Actualización sobre los medicamentos biocomparables en la enfermedad inflamatoria intestinal: posición y recomendación en México

Gupta, 2017, Sophisticated cloning, fermentation, and purification technologies for an enhanced therapeutic protein production: A review, Front Pharmacol., 8, 419, 10.3389/fphar.2017.00419 Stryjewska, 2013, Biotechnology and genetic engineering in the new drug development. Part I. DNA technology and recombinant proteins, Pharmacol Rep., 65, 1075, 10.1016/S1734-1140(13)71466-X Murdaca, 2009, Anti-TNF-alpha inhibitors: A new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events, Int J Immunopathol Pharmacol., 22, 557, 10.1177/039463200902200301 Rinaudo Gaujous, 2013, Review article: Biosimilars are the next generation of drugs for liver and gastrointestinal diseases, Aliment Pharmacol Ther., 38, 914, 10.1111/apt.12477 Gabbani, 2017, CT-P13: Design, development, and place in therapy, Drug Des Devel Ther., 11, 1653, 10.2147/DDDT.S109852 Park, 2013, A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study, Ann Rheum Dis., 72, 1605, 10.1136/annrheumdis-2012-203091 Yoo, 2013, A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study, Ann Rheum Dis., 72, 1613, 10.1136/annrheumdis-2012-203090 Ben-Horin, 2016, Biosimilars in inflammatory bowel disease: Facts and fears of extrapolation, Clin Gastroenterol Hepatol., 14, 1685, 10.1016/j.cgh.2016.05.023 Jorgensen, 2017, Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomised, double-blind, non-inferiority trial, Lancet., 389, 2304, 10.1016/S0140-6736(17)30068-5 Eberl, 2017, Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients, Scand J Gastroenterol., 52, 1378, 10.1080/00365521.2017.1369561 Farkas, 2017, Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis-experiences from a single center, Expert Opin Biol Ther., 17, 1325 Smits, 2017, Long-term clinical outcomes after switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease., 62, 3117 Jung, 2015, Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study, J Gastroenterol Hepatol, 30, 1705, 10.1111/jgh.12997 Argüelles Arias, 2017, Effectiveness and safety of CT-P13 (biosimilar infliximab) in patients with inflammatory bowel disease in real life at 6 months, Dig Dis Sci, 62, 1305, 10.1007/s10620-017-4511-4 Park, 2015, Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea, Expert Rev Gastroenterol Hepatol., 9, 35, 10.1586/17474124.2015.1091309 Fiorino, 2017, The PROSIT-BIO cohort: A prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar, Inflamm Bowel Dis., 23, 233, 10.1097/MIB.0000000000000995 Guerrero Puente, 2017, Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission, Gastroenterol Hepatol., 40, 595, 10.1016/j.gastrohep.2017.07.005 Sieczkowska, 2016, Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations, J Crohńs Colitis., 10, 127, 10.1093/ecco-jcc/jjv233 Komaki, 2017, Systematic review with meta-analysis: The efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases, Aliment Pharmacol Ther., 45, 1043, 10.1111/apt.13990 Ley General de Salud, art. 222 bis, título xii: Control sanitario de productos y servicios y de su importación y exportación. Capítulo iv: Medicamentos. NORMA Oficial Mexicana NOM-257-SSA1-2014, en materia de medicamentos biotecnológicos. NORMA Oficial Mexicana NOM-177-SSA1-2013, que establece las pruebas y procedimientos para demostrar que un medicamento es intercambiable. NORMA Oficial Mexicana NOM-220-SSA1-2016, instalación y operación de la farmacovigilancia. Kurki, 2017, Interchangeability of biosimilars: A European perspective, BioDrugs., 31, 83, 10.1007/s40259-017-0210-0 Daller, 2016, Biosimilars: A consideration of the regulations in the United States and European Union, Regul Toxicol Pharmacol., 76, 199, 10.1016/j.yrtph.2015.12.013 US Department of Health and Human Services, Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product. Guidance for industry. Food and Drug Administration; 2017. Pecoraro, 2017, The impact of immunogenicity of TNFα inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis, Autoimmun Rev., 16, 564, 10.1016/j.autrev.2017.04.002 Van Beers, 2012, Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins, Biotechnol J., 7, 1473, 10.1002/biot.201200065 Ben Horin, 2016, Cross-immunogenicity: Antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima, Gut., 65, 1132, 10.1136/gutjnl-2015-309290 Baert, 2003, Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease, N Engl J Med., 348, 601, 10.1056/NEJMoa020888 Farrell, 2003, Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial, Gastroenterology., 124, 917, 10.1053/gast.2003.50145 Bálint, 2017, Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: Results from Central European nationwide cohort, Expert Opin Drug Saf, 16, 885, 10.1080/14740338.2017.1323330 Hindryckx, 2017, Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease: A practical overview, Drugs., 77, 363, 10.1007/s40265-017-0693-5 Giezen, 2010, Mapping the safety profile of biologicals: A disproportionality analysis using the WHO adverse drug reaction database VigiBase, Drug Saf., 33, 865, 10.2165/11538330-000000000-00000 Park, 2017, Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study, Ann Rheum Dis., 76, 346, 10.1136/annrheumdis-2015-208783 Yoo, 2017, Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study, Ann Rheum Dis., 76, 355, 10.1136/annrheumdis-2015-208786 Ley General de Salud. Reglamento de insumos para la salud, título sexto: autorizaciones y avisos. Capítulo III: Registros. Art. 177 bis-2, bis-5. Chang, 2017, Extrapolation and interchangeability of infliximab and adalimumab in inflammatory bowel disease, Curr Treat Options Gastroenterol., 15, 53, 10.1007/s11938-017-0122-6 Schellekens, 2015, Biosimilar monoclonal antibodies: The scientific basis for extrapolation, Expert Opin Biol Ther., 15, 1633, 10.1517/14712598.2015.1083552 McConachie, 2017, Biosimilars in inflammatory bowel disease-accumulating clinical evidence, Expert Rev Clin Pharmacol., 10, 391, 10.1080/17512433.2017.1283983 Ben Horin, 2016, Biosimilars in inflammatory bowel disease: Facts and fears of extrapolation, Clin Gastroenterol Hepatol., 14, 1685, 10.1016/j.cgh.2016.05.023 Eder, 2016, Update on the mechanisms of action of anti-TNF-α antibodies and their clinical implications in inflammatory bowel disease, Pol Arch Med Wewn., 126, 772